Advertisement

Archives of Dermatological Research

, Volume 301, Issue 1, pp 57–64 | Cite as

Prediction and prevention of autoimmune skin disorders

  • Agmon-Levin Nancy
  • Shoenfeld YehudaEmail author
Review

Abstract

Autoimmune diseases can be preceded by a symptom-free phase which is defined by the presence of autoantibodies, and may last for many years. These autoantibodies may have a high positive predictive value for disease onset, severity and organ-specific complications, especially in genetically prone individuals. Characteristic autoantibodies and susceptible genes have been identified in many autoimmune systemic and mucocutaneous diseases such as systemic lupus erythematosus, pemphigus, vitiligo, dermatitis hepretiformis and even psoriasis. Prevention of overt disease may be achieved once high-risk individuals are identified and triggering factors are avoided. Numerous environmental factors, such as vitamin D deficiency, ultraviolet light, smoking, drugs, etc., that may trigger autoimmunity have been found. Alternatively, even if the autoimmune disease cannot be prevented, it may be postponed or attenuated. Thus, although large body of evidence has accumulated on characteristic autoantibodies, susceptible genes and environmental factors, many more large scale studies are needed to assess their predictive value, the preventive measurements and the means to apply them to clinical management of healthy population and high-risk individuals.

Keywords

Autoimmunity Prevention Skin diseases Genetics Environmental factors 

Notes

Conflict of interest statement

The authors have no potential conflict of interest.

References

  1. 1.
    Aharon MA, Shoenfeld Y (1988) The role of ultraviolet light, and sun and fluorescent light, in the pathogenesis of systemic lupus erythemaosus. Harefuah 135:295–299Google Scholar
  2. 2.
    Alkhateeb A, Fain PR, Thody A et al (2003) Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res 16:208–214. doi: 10.1034/j.1600-0749.2003.00032.x PubMedCrossRefGoogle Scholar
  3. 3.
    Arbuckle MR, McClain MT, Rubertone MV et al (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349(16):1526–1533. doi: 10.1056/NEJMoa021933 PubMedCrossRefGoogle Scholar
  4. 4.
    Arnson Y, Amital H, Shoenfeld Y (2007) Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis 66:1137–1142. doi: 10.1136/ard.2007.069831 PubMedCrossRefGoogle Scholar
  5. 5.
    Baharav E, Merimski O, Shoenfeld Y et al (1996) Tyrosinase as an autoantigen in patients with vitiligo. Clin Exp Immunol 105:84–88. doi: 10.1046/j.1365-2249.1996.d01-727.x PubMedCrossRefGoogle Scholar
  6. 6.
    Bizzaro N, Tozzoli R, Shoenfeld Y (2007) Are we at a stage to predict autoimmune rheumatic diseases? Arthritis Rheum 56:1736–1744. doi: 10.1002/art.22708 PubMedCrossRefGoogle Scholar
  7. 7.
    Bizzaro N (2008) The predictive significance of autoantibodies in organ-specific autoimmune diseases. Clin Rev Allergy Immunol 34(3):326–331PubMedCrossRefGoogle Scholar
  8. 8.
    Blank M, Gisondi P, Mimouni D et al (2006) New insights into the autoantibody-mediated mechanisms of autoimmune bullous diseases and urticaria. Clin Exp Rheumatol 24(1 Suppl 40):S20–S25PubMedGoogle Scholar
  9. 9.
    Brenner S (1999) Pemphigus and diet. Have we solved the mystery of fogo selvagem? Adv Exp Med Biol 455:267–269PubMedGoogle Scholar
  10. 10.
    Burden AD, Javed S, Bailey M et al (1998) Genetics of psoriasis: paternal inheritance and a locus on chromosome 6p. J Invest Dermatol 110:958–960. doi: 10.1046/j.1523-1747.1998.00213.x PubMedCrossRefGoogle Scholar
  11. 11.
    Cancino-Díaz ME, Ruiz-González V, Ramírez-Reséndiz L et al (2004) IgG class antibodies from psoriasis patients recognize the 60-KDa heat-shock protein of Streptococcus pyogenes. Int J Dermatol 43:341–347. doi: 10.1111/j.1365-4632.2004.01884.x PubMedCrossRefGoogle Scholar
  12. 12.
    Cardinali C, Caproni M, Bernacchi E et al (2000) The spectrum of cutaneous manifestations in lupus erythematosus—the Italian experience. Lupus 9:417–423. doi: 10.1191/096120300678828569 PubMedCrossRefGoogle Scholar
  13. 13.
    Caricchio R, McPhie L, Cohen P (2003) Ultraviolet B radiation induced cell death: critical role of ultraviolet dose in inflammation and lupus autoantigen redistribution. J Immunol 171:5778–5786PubMedGoogle Scholar
  14. 14.
    Carvalho JF, Blank M, Kiss E et al (2007) Anti-vitamin D, vitamin D in SLE: preliminary results. Ann NY Acad Sci 1109:550–557. doi: 10.1196/annals.1398.061 PubMedCrossRefGoogle Scholar
  15. 15.
    Christen U, Edelmann KH, McGavern DB et al (2004) A viral epitope that mimics a self antigen can accelerate but not initiate autoimmune diabetes. J Clin Invest 114:1290–1298PubMedGoogle Scholar
  16. 16.
    Collin P, Reunala T (2003) Recognition and management of the cutaneous manifestations of celiac disease: a guide for dermatologists. Am J Clin Dermatol 4:13–20. doi: 10.2165/00128071-200304010-00002 PubMedCrossRefGoogle Scholar
  17. 17.
    Femiano F (2007) Pemphigus vulgaris: recent advances in our understanding of its pathogenesis. Minerva Stomatol 56:215–223PubMedGoogle Scholar
  18. 18.
    Fry L, Baker BS (2007) Triggering psoriasis: the role of infections and medications. Clin Dermatol 25:606–615. doi: 10.1016/j.clindermatol.2007.08.015 PubMedCrossRefGoogle Scholar
  19. 19.
    Furukawa F, Yoshimasu T (2005) Animal models of spontaneous and drug induced cutaneous lupus erythematosus. Autoimmun Rev 4:345–350. doi: 10.1016/j.autrev.2005.01.006 PubMedCrossRefGoogle Scholar
  20. 20.
    Gershwin ME, Mackay IR (2008) The causes of primary biliary cirrhosis: convenient and inconvenient truths. Hepatology 47:737–745. doi: 10.1002/hep.22042 PubMedCrossRefGoogle Scholar
  21. 21.
    Grando SA (2007) Autoantibodies to mucocutaneous antigens. In: Shoenfeld Y, Gershwin ME, Meroni PL (eds) AUTOantibodies, 2nd edn, chap 95, p 765Google Scholar
  22. 22.
    Griffiths CE, Iaccarino L, Naldi L et al (2006) Psoriasis and psoriatic arthritis: immunological aspects and therapeutic guidelines. Clin Exp Rheumatol 24(1 Suppl 40):S72–S78PubMedGoogle Scholar
  23. 23.
    Grimes PE (2005) New insights and new therapies in vitiligo. JAMA 293:730–735. doi: 10.1001/jama.293.6.730 PubMedCrossRefGoogle Scholar
  24. 24.
    Grootscholten C, van Bruggen MC, van der Pijl JW et al (2003) Deposition of nucleosomal antigens (histones and DNA) in the epidermal basement membrane in human lupus nephritis. Arthritis Rheum 48:1355–1362. doi: 10.1002/art.10974 PubMedCrossRefGoogle Scholar
  25. 25.
    Guandalini S (2007) The influence of gluten: weaning recommendations for healthy children and children at risk for celiac disease. Nestle Nutr Workshop Ser Pediatr Program 60:139–151. doi: 10.1159/000106366 PubMedCrossRefGoogle Scholar
  26. 26.
    Gudjonsson JE, Elder JT (2007) Psoriasis: epidemiology. Clin Dermatol 25:535–546. doi: 10.1016/j.clindermatol.2007.08.007 PubMedCrossRefGoogle Scholar
  27. 27.
    Harel M, Shoenfeld Y (2006) Predicting and preventive autoimmunity, myth or reality? Ann N Y Acad Sci 1069:322–345. doi: 10.1196/annals.1351.031 PubMedCrossRefGoogle Scholar
  28. 28.
    Harley JB, Kelly JA, Kaufman KM (2006) Unraveling the genetics of systemic lupus erythematosus. Springer Semin Immunopathol 28:119–130. doi: 10.1007/s00281-006-0040-5 PubMedCrossRefGoogle Scholar
  29. 29.
    Herron MD, Hinckley M, Hoffman MS et al (2005) Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 141:1527–1534. doi: 10.1001/archderm.141.12.1527 PubMedCrossRefGoogle Scholar
  30. 30.
    Humbert P, Pelletier F, Dreno B et al (2006) Gluten intolerance and skin diseases. Eur J Dermatol 16:4–11PubMedGoogle Scholar
  31. 31.
    Israeli E, Grotto I, Gilburd B et al (2005) Cytoplasmic antibodies as predictors of Anti-Saccharomyces cerevisiae and antineutrophil inflammatory bowel disease. Gut 54:1232–1236. doi: 10.1136/gut.2004.060228 PubMedCrossRefGoogle Scholar
  32. 32.
    Itirli G, Pehlivan M, Alper S et al (2005) Exon-3 polymorphism of CTLA-4 gene in Turkish patients with vitiligo. J Dermatol Sci 38:225–227. doi: 10.1016/j.jdermsci.2005.03.003 PubMedCrossRefGoogle Scholar
  33. 33.
    Karell K, Korponay-Szabo I, Szalai Z et al (2002) Genetic dissection between coeliac disease and dermatitis herpetiformis in sib pairs. Ann Hum Genet 66(Pt 5–6):387–392. doi: 10.1046/j.1469-1809.2002.00128.x PubMedCrossRefGoogle Scholar
  34. 34.
    Kemp EH, Waterman EA, Gawkrodger DJ et al (1998) Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay. Br J Dermatol 139:798–805. doi: 10.1046/j.1365-2133.1998.02503.x PubMedCrossRefGoogle Scholar
  35. 35.
    Kemp EH, Gawkrodger DJ, Watson PF, Weetman AP (1998) Autoantibodies to human melanocyte-specific protein Pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay. Clin Exp Immunol 114:333–338. doi: 10.1046/j.1365-2249.1998.00746.x RIAPubMedCrossRefGoogle Scholar
  36. 36.
    Kemp EH, Gavalas NG, Gawkrodger DJ, Weetman AP (2007) Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo. Autoimmun Rev 6:138–142. doi: 10.1016/j.autrev.2006.09.010 PubMedCrossRefGoogle Scholar
  37. 37.
    Kent G, Al’ Abadie MSK (1996) Psychologic effects of vitiligo: a critical incident analysis. J Am Acad Dermatol 35:895–898. doi: 10.1016/S0190-9622(96)90112-7 PubMedCrossRefGoogle Scholar
  38. 38.
    Kricheli D, David M, Frusic-Zlotkin M (2000) The distribution of pemphigus vulgaris-IgG subclasses and their reactivity with desmoglein 3 and 1 in pemphigus patients and their first-degree relatives. Br J Dermatol 143(2):337–342. doi: 10.1046/j.1365-2133.2000.03659.x PubMedCrossRefGoogle Scholar
  39. 39.
    Kupila A, Muona P, Simell T et al (2001) Juvenile Diabetes Research Foundation Center for the Prevention of Type 1 Diabetes in Finland. Feasibility of genetic and immunological prediction of type 1 diabetes in a population-based birth cohort. Diabetologia 44:290–297. doi: 10.1007/s001250051616 PubMedCrossRefGoogle Scholar
  40. 40.
    Lee E, Lendas KA, Chow S et al (2006) Disease relevant HLA class II alleles isolated by genotypic, haplotypic, and sequence analysis in North American Caucasians with pemphigus vulgaris. Hum Immunol 67(1–2):125–139. doi: 10.1016/j.humimm.2005.09.003 PubMedCrossRefGoogle Scholar
  41. 41.
    Luszczek W, Kubicka W, Jasek M et al (2006) CTLA-4 gene polymorphisms and natural soluble CTLA-4 protein in psoriasis vulgaris. Int J Immunogenet 33(3):217–224. doi: 10.1111/j.1744-313X.2006.00600.x PubMedCrossRefGoogle Scholar
  42. 42.
    MacDonald A, Burden AD (2007) Psoriasis: advances in pathophysiology and management. Postgrad Med J 83:690–697. doi: 10.1136/pgmj.2007.061473 PubMedCrossRefGoogle Scholar
  43. 43.
    Matsushita Y, Shimada Y, Kawara S et al (2005) Autoantibodies directed against the protease inhibitor calpastatin in psoriasis. Clin Exp Immunol 139:355–362. doi: 10.1111/j.1365-2249.2005.02701.x PubMedCrossRefGoogle Scholar
  44. 44.
    Matz H, Tur E (2007) Vitiligo. Curr Probl Dermatol 35:78–102. doi: 10.1159/000106412 PubMedCrossRefGoogle Scholar
  45. 45.
    Morris A, Rogers M, Fischer G et al (2001) Childhood psoriasis: a clinical review of 1262 cases. Pediatr Dermatol 18:188–198. doi: 10.1046/j.1525-1470.2001.018003188.x PubMedCrossRefGoogle Scholar
  46. 46.
    Naldi L, Chatenoud L, Linder D et al (2005) Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 125:61–67. doi: 10.1111/j.0022-202X.2005.23681.x PubMedCrossRefGoogle Scholar
  47. 47.
    Oyarbide-Valencia K, van den Boorn JG (2006) Therapeutic implications of autoimmune vitiligo T cells. Autoimmun Rev 5:486–492. doi: 10.1016/j.autrev.2006.03.012 PubMedCrossRefGoogle Scholar
  48. 48.
    Pias EK, Hilario-Vargas J, Li N, Diaz LA (2004) Humoral autoimmunity in pemphigus. Autoimmunity 37:283–286. doi: 10.1080/08916930410001710848 PubMedCrossRefGoogle Scholar
  49. 49.
    Rahman A, Isenberg DA (2008) Systemic Lupus Erythematosus. N Engl J Med 358:929–939. doi: 10.1056/NEJMra071297 PubMedCrossRefGoogle Scholar
  50. 50.
    Ram M, Shoenfeld Y (2007) Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality? Ann NY Acad Sci 1110:410–425. doi: 10.1196/annals.1423.043 PubMedCrossRefGoogle Scholar
  51. 51.
    Reichrath J (2007) Vitamin D and the skin: an ancient friend, revisited. Exp Dermatol 16:618–625. doi: 10.1111/j.1600-0625.2007.00570.x PubMedCrossRefGoogle Scholar
  52. 52.
    Rezaei N, Gavalas NG, Weetman AP, Kemp EH (2007) Autoimmunity as an aetiological factor in vitiligo. J Eur Acad Dermatol Venereol 21:865–876. doi: 10.1111/j.1468-3083.2007.02228.x PubMedCrossRefGoogle Scholar
  53. 53.
    Rioux JD, Abbas AK (2005) Pathways to understanding the genetic basis of autoimmune diseases. Nature 435:584–589. doi: 10.1038/nature03723 PubMedCrossRefGoogle Scholar
  54. 54.
    Ruiz-Argüelles A, Brito GJ, Reyes-Izquierdo P et al (2007) Apoptosis of melanocytes in vitiligo results from antibody penetration. J Autoimmun 29:281–286. doi: 10.1016/j.jaut.2007.07.012 PubMedCrossRefGoogle Scholar
  55. 55.
    Ruocco E, Aurilia A, Ruocco V (2001) Percautions and suggestions for pemphigus patients. Dermatology 203:201–207. doi: 10.1159/000051749 PubMedCrossRefGoogle Scholar
  56. 56.
    Scofield RH (2004) Autoantibodies as predictors of disease. Lancet 363:1544. doi: 10.1016/S0140-6736(04)16154-0 PubMedCrossRefGoogle Scholar
  57. 57.
    Sehpshelovich D, Shoenfeld Y (2006) Prediction and prevention of autoimmune diseases. Lupus 15:183–189. doi: 10.1191/0961203306lu2274rr CrossRefGoogle Scholar
  58. 58.
    Selmi C, Mayo MJ, Bach N et al (2004) Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics and environment. Gastroenterology 127:485–492. doi: 10.1053/j.gastro.2004.05.005 PubMedCrossRefGoogle Scholar
  59. 59.
    Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y (2004) Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 34:501–537. doi: 10.1016/j.semarthrit.2004.07.002 PubMedCrossRefGoogle Scholar
  60. 60.
    Shoenfeld Y, Rose NR (2004) Introduction: infection and autoimmunity. In: Shoenfeld Y, Rose NR (eds) Infection and autoimmunity. Elsevier, AmsterdamGoogle Scholar
  61. 61.
    Shoenfeld Y, Blank M, Abu-Shakra M (2008) The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases. Isr Med Assoc J 10(1):13–19PubMedGoogle Scholar
  62. 62.
    Shoenfeld Y, Zandman-Goddard G, Stojanovich L (2008) The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases—2008. Isr Med Assoc J 10:8–12PubMedGoogle Scholar
  63. 63.
    Shoenfeld Y, Gilburd B, Abu-Shakra M et al (2008) The mosaic of autoimmunity: genetic factors involved in autoimmune diseases—2008. Isr Med Assoc J 10:3–7PubMedGoogle Scholar
  64. 64.
    Shovman O, Gilburd B, Zandman-Goddard G et al (2006) Pathogenic role and clinical relevance of antineutrophil cytoplasmic antibodies in vasculitides. Curr Rheumatol Rep 8:292–298. doi: 10.1007/s11926-006-0012-8 PubMedCrossRefGoogle Scholar
  65. 65.
    Sullivan KE (2000) Genetics of systemic lupus erythematosus: clinical implications. Rheum Dis Clin North Am 26:229–256. doi: 10.1016/S0889-857X(05)70137-X PubMedCrossRefGoogle Scholar
  66. 66.
    Torzecka JD, Woźniak K, Kowalewski C (2007) Circulating pemphigus autoantibodies in healthy relatives of pemphigus patients: coincidental phenomenon with a risk of disease development? Arch Dermatol Res 299:239–243. doi: 10.1007/s00403-007-0760-y PubMedCrossRefGoogle Scholar
  67. 67.
    Tran TT, Pisetsky DS (2004) Systemic lupus erythematosus and related diseases. Autoimmunity 37:301–304. doi: 10.1080/08916930410001708698 PubMedCrossRefGoogle Scholar
  68. 68.
    Trembath RC, Clough RL, Rosbotham JL et al (1997) Identification of a major susceptibility locus on chromosome 6p and evidence of further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 6:813–820. doi: 10.1093/hmg/6.5.813 PubMedCrossRefGoogle Scholar
  69. 69.
    Wanstrat A, Wakeland E (2001) The genetics of complex autoimmune diseases: non-MHC susceptibility genes. Nat Immunol 2:802–809. doi: 10.1038/ni0901-802 CrossRefGoogle Scholar
  70. 70.
    Zhang XJ, Chen JJ, Liu JB (2005) The genetic concept of vitiligo. J Dermatol Sci 39:137–146. doi: 10.1016/j.jdermsci.2005.06.004 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Department of Medicine ‘B’, Center for Autoimmune DiseasesChaim Sheba Medical CenterTel-Hashomer, Tel AvivIsrael
  2. 2.Sackler Faculty of Medicine, Incumbent of the Laura Schwarz-Kip Chair for Research of Autoimmune DiseasesTel-Aviv UniversityTel AvivIsrael

Personalised recommendations